$RDHL News
Last published 3w ago
- 3w agoRDHL$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple MyelomaPR NewswireTEL AVIV, Israel and RALEIGH, N.C., Oct. 19, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its
- 1mo agoRDHLRedHill Biopharma Announces Operational Highlights and First Half 2026 Financial ResultsPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported operational highlights and...
- 2mo agoRDHLRedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®PR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the transformational...
- 2mo agoRDHLRedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®GlobeNewswireTogether with the previously announced Talicia strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that
- 2mo agoRDHLRedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth OpportunitiesPR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the divestment of its...
- 3mo agoRDHLEbola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak DevelopmentPR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today provided an update on the...
- 4mo agoRDHLRedHill Biopharma Announces Closing of Up To $19.4 Million Private PlacementPR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its...
- 4mo agoRDHLCPIXRedHill Biopharma Announces Up To $19.4 Million Private PlacementPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a ...
- 5mo agoRDHLCPIXRedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug DesignationPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Food and...
- 5mo agoRDHLCPIXRedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against KukboPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has commenced...
- 5mo agoRDHLRedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease OutbreakPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it is actively...
- 5mo agoRDHLCPIXRedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense PlatformsPR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it is actively...
- 6mo agoRDHLCPIXRedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's DiseasePR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new in vitro testing...
- 6mo agoCPIXRDHLRedHill Biopharma Announces Full-Year 2025 Financial Results and Operational HighlightsPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its full-year 2025...
- 6mo agoRDHLCPIXRedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026PR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the independent...
- 8mo agoRDHLCPIXPHATH. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsightPR NewswireRecently published H. pylori Infections Market Insights report includes a comprehensive understanding of current treatment practices, H. pylori...
- 8mo agoCMPXMRKSGENPFE+8Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsightPR NewswireThe biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing...
- 8mo agoRDHLCPIXJoint U.S. Commercialization of RedHill's Talicia® CommencesPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the full sales and...
- 10mo agoRDHLRedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side EffectsPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced development progress for...
- 11mo agoRDHLRedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant CellsPR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced positive in vivo results,...
- 11mo agoRDHLRedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity RequirementPR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on November 26, 2025, ...
- 1y agoRDHLRedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for EnforcementPR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York Supreme...
- 1y agoRDHLRedHill Biopharma Receives Nasdaq Staff Determination NotificationPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on October 16, 2025,...
- 1y agoCPIXRDHLCUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIOPR NewswireCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient...
- 1y agoCPIXRDHLRedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership DealPR NewswireRedHill Biopharma Limited (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the signing of a...
- 1y agoRDHLRedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®PR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the licensing of Talicia...
- 1y agoRDHLRedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against KukboPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that The New York Supreme...
- 1y agoRDHLRedHill Biopharma Announces First Half 2025 Financial Results and Operational HighlightsPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its first half of 2025...
- 1y agoRDHLRedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment WinPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York Supreme...
- 1y agoRDHLRedHill Received Talicia® Licensing Payments Totaling $1.1 MillionPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has received its...
- 1y agoRDHLRedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's DiseasePR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received positive...
- 1y agoRDHLRedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate CancerPR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the initiation of patient...
- 1y agoRDHLRedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment WinPR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it had won its...
- 1y agoRDHLRedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology CongressPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its support of an...
- 1y agoRDHLRedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107PR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the China National...
- 1y agoRDHLRedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity DeficiencyPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company received...
- 1y agoRDHLRedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market DisruptionPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the new publication[2] of...
- 1y agoRDHLRedHill Biopharma Announces Full-Year 2024 Financial Results and Operational HighlightsPR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its full-year 2024...
- 1y agoRDHLRedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing AuthorisationPR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its plan to submit a UK...
- 1y agoRDHLRedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 ResultsPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced plans to advance its...
- 1y agoRDHLRedHill Presents Business Update at the Sachs' European Life Sciences CEO ForumPR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the presentation of a...
- 1y agoRDHLRedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus RoyaltiesPR NewswireRedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into...
- 1y agoRDHLRedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate CancerPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the initiation of a Phase...
- 1y agoRDHLRedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing PublishedPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the coverage of Talicia by ...
- 1y agoRDHLRadioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced DevelopmentPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced positive results from new...
- 1y agoRDHLRedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme CourtPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company has been...
- 2y agoATNMRDHLAVTXTENXActinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of DirectorsPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs)...
- 2y agoRDHLRedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRNDPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company has been...
- 2y agoRDHLRedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation InjuryPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the signing of a...
- 2y agoRDHLRedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola TreatmentPR NewswireRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. government's ...